{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:49:33Z","timestamp":1760906973483},"reference-count":24,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.3892\/ol.2013.1232","type":"journal-article","created":{"date-parts":[[2013,3,6]],"date-time":"2013-03-06T08:11:54Z","timestamp":1362557514000},"page":"1601-1604","source":"Crossref","is-referenced-by-count":3,"title":["Complete remission of platinum-refractory primary Fallopian tube carcinoma with third-line gemcitabine plus cisplatin: A case report and review of the literature"],"prefix":"10.3892","volume":"5","author":[{"given":"QIUYI","family":"XU","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NONG","family":"XU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WEIJIA","family":"FANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PENG","family":"ZHAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHENYU","family":"MAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YULONG","family":"ZHENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HAIBO","family":"MOU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,3,6]]},"reference":[{"key":"key20180108092758_b1-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ijc.10970","article-title":"Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953\u201397","volume":"104","author":"Riska","year":"2003","journal-title":"Int J Cancer"},{"key":"key20180108092758_b2-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0090-8258(03)00399-8","article-title":"Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer","volume":"90","author":"Markman","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"Suppl 5","key":"key20180108092758_b3-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"v188","DOI":"10.1093\/annonc\/mdj979","article-title":"Role of gemcitabine in ovarian cancer treatment","volume":"17","author":"Lorusso","year":"2006","journal-title":"Ann Oncol"},{"key":"key20180108092758_b4-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ygyno.2007.09.018","article-title":"The incidence of primary fallopian tube cancer in the United States","volume":"107","author":"Stewart","year":"2007","journal-title":"Gynecol Oncol"},{"key":"key20180108092758_b5-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/01.ogx.0000158506.23663.79","article-title":"Primary fallopian tube carcinoma","volume":"60","author":"Ajithkumar","year":"2005","journal-title":"Obstet Gynecol Surv"},{"key":"key20180108092758_b6-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/1097-0142(20001001)89:7<1555::AID-CNCR20>3.0.CO;2-J","article-title":"The clinical value of serum concentrations of cancer antigen 125 in patients with primary fallopian tube carcinoma: a multicenter study","volume":"89","author":"Hefler","year":"2000","journal-title":"Cancer"},{"key":"key20180108092758_b7-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1002\/cncr.23957","article-title":"Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer","volume":"113","author":"Wethington","year":"2008","journal-title":"Cancer"},{"key":"key20180108092758_b8-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0959-8049(98)00214-7","article-title":"A 15-year overview of management and prognosis in primary fallopian tube carcinoma. Austrian Cooperative Study Group for Fallopian Tube Carcinoma","volume":"34","author":"Rosen","year":"1998","journal-title":"Eur J Cancer"},{"key":"key20180108092758_b9-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/00016340701771034","article-title":"Updating on primary fallopian tube carcinoma","volume":"86","author":"Riska","year":"2007","journal-title":"Acta Obstet Gynecol Scand"},{"key":"key20180108092758_b10-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000151668","article-title":"Paclitaxel- and platinum-based postoperative chemotherapy for primary fallopian tube carcinoma: a single institution experience","volume":"75","author":"Papadimitriou","year":"2008","journal-title":"Oncology"},{"key":"key20180108092758_b11-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1006\/gyno.2001.6134","article-title":"Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study","volume":"81","author":"Gadducci","year":"2001","journal-title":"Gynecol Oncol"},{"key":"key20180108092758_b12-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ygyno.2009.06.025","article-title":"Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients","volume":"115","author":"Pectasides","year":"2009","journal-title":"Gynecol Oncol"},{"key":"key20180108092758_b13-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1002\/1097-0142(20001115)89:10<2076::AID-CNCR7>3.0.CO;2-V","article-title":"Carcinoma of the fallopian tube","volume":"89","author":"Baekelandt","year":"2000","journal-title":"Cancer"},{"key":"key20180108092758_b14-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1006\/gyno.1995.1222","article-title":"Primary fallopian tube adenocarcinoma: clinical complete response after salvage treatment with high-dose paclitaxel","volume":"58","author":"Tresukosol","year":"1995","journal-title":"Gynecol Oncol"},{"key":"key20180108092758_b15-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1006\/gyno.1999.5630","article-title":"Complete response to topotecan of recurrent fallopian tube carcinoma","volume":"76","author":"Dunton","year":"2000","journal-title":"Gynecol Oncol"},{"key":"key20180108092758_b16-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1517\/13543784.2010.515585","article-title":"Overcoming platinum resistance in ovarian carcinoma","volume":"19","author":"Matsuo","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"key20180108092758_b17-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.bjc.6690452","article-title":"Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines","volume":"80","author":"van Moorsel","year":"1999","journal-title":"Br J Cancer"},{"key":"key20180108092758_b18-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/gyno.2002.6850","article-title":"Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol Oncol"},{"key":"key20180108092758_b19-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/gyno.2002.6855","article-title":"Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients","volume":"88","author":"Nagourney","year":"2003","journal-title":"Gynecol Oncol"},{"key":"key20180108092758_b20-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1023\/B:DRUG.0000036690.14585.a3","article-title":"Gemcitabine and cisplatin chemotherapy an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma","volume":"22","author":"Tewari","year":"2004","journal-title":"Invest New Drugs"},{"key":"key20180108092758_b21-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ygyno.2006.03.018","article-title":"Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group","volume":"103","author":"Brewer","year":"2006","journal-title":"Gynecol Oncol"},{"key":"key20180108092758_b22-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ygyno.2006.09.006","article-title":"Biweekly gemcitabine and cisplatin in platinum-resistant\/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma","volume":"104","author":"Bozas","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"Suppl 1","key":"key20180108092758_b23-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1525-1438.2005.15357.x","article-title":"Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma","volume":"15","author":"Rose","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"key20180108092758_b24-ol-05-05-1601","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/IGC.0b013e3182049273","article-title":"Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube","volume":"21","author":"Griffiths","year":"2011","journal-title":"Int J Gynecol Cancer"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2013.1232\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T05:49:41Z","timestamp":1515390581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2013.1232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,6]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,3,6]]},"published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.3892\/ol.2013.1232"],"URL":"https:\/\/doi.org\/10.3892\/ol.2013.1232","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,6]]}}}